Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study

• Published in: Biomedicines Vol. 10; no. 7; p. 1737
• Main Authors: Kuzmanovszki, Daniella, Kiss, Norbert, Tóth, Béla, Kerner, Tünde, Tóth, Veronika, Szakonyi, József, Lőrincz, Kende, Hársing, Judit, Imrédi, Eleonóra, Pfund, Alexa, Szabó, Ákos, Brodszky, Valentin, Rencz, Fanni, Holló, Péter
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.07.2022; MDPI
• Subjects: advanced melanoma; adverse event; Adverse events; anti-PD-1 monotherapy; Antibodies; Clinical outcomes; Clinical trials; Cytotoxicity; Data collection; Disease; Drug dosages; Electronic health records; immune checkpoint inhibitor; Immune checkpoint inhibitors; Ligands; Lymphocytes; Melanoma; Metastasis; Mutation; nivolumab; Observational studies; Patients; PD-1 protein; Pembrolizumab; Survival; Toxicity; Hungary

Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adve...